SML2292
CCG-100602
≥98% (HPLC)
别名:
1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-3-piperidinecarboxamide, 1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide, CCG 100602, CCG100602
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
O=C(N1CCCC(C(NC2=CC=C(Cl)C=C2)=O)C1)C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3
InChI
1S/C21H17ClF6N2O2/c22-16-3-5-17(6-4-16)29-18(31)12-2-1-7-30(11-12)19(32)13-8-14(20(23,24)25)10-15(9-13)21(26,27)28/h3-6,8-10,12H,1-2,7,11H2,(H,29,31)
InChI key
MOQCFMZWVKQBAP-UHFFFAOYSA-N
Biochem/physiol Actions
CCG-100602 aids in preventing fibrosis around the temporomandibular joint (TMJ).
CCG-100602 is a CCG-1423 analog with significantly less cytotoxicity (0/14% WST-1 inhibition by 10/100 μM CCG-100602 vs. 44% by 10 μM CCG-1423) and similar efficacy against Rho/MKL1/SRF pathway-mediated transcription (by 78% with 100 μM CCG-100602 vs. 74% with 10 μM CCG-1423; IC50 = 9.8 μM/CCG-100602 vs. 1.5 μM/CCG-1423; by PC-3 SRE-luciferase assay), albeit at a reduced potency. CCG-100602 reduces the stiffening of spontaneously hypertensive rats (SHR) derived aortic VSMCs (1.12 μM) by inhibiting SRF/myocardin interaction and abrogates the increased aortic wall stiffness in SHR rats in vivo (7.5 mg/kg/d via s.c. osmotic pumps for 2 wks).
CCG-1423 analog with similar efficacy and much less cytotoxicity. Inhibits SRF/myocardin interaction and reduces aortic VSMCs stiffening in vitro and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2292-5MG | 04061835350155 |
| SML2292-25MG | 04061835350148 |